Q-omics provides the consensus-scored CLUHP3 profile across patient tissues and cancer cell-line models. CLUHP3 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CLUHP3 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, CLUHP3 RNA expression shows 19,491 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, COAD, and THYM as cancer lineages where CLUHP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CLUHP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CLUHP3 survival associations across molecular data types. CLUHP3 RNA expression shows survival associations in the most cancer types (21), followed by mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CLUHP3 RNA expression–survival associations across cancer types. High CLUHP3 expression shows unfavorable associations in COAD, but favorable associations in MESO, PAAD, UVM, READ and BRCA. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for CLUHP3 RNA expression.
This table summarizes CLUHP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CLUHP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CLUHP3 shows lower tumor expression in THCA, KICH and KIRC and higher tumor expression in COAD, STAD and LIHC. The COAD box plot shows higher CLUHP3 RNA expression in tumor versus normal tissue (log2 FC = +0.998, t-test p < 0.001).
This table shows molecular features associated with CLUHP3 in patient tissues and cancer cell lines. In patient samples, CLUHP3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CLUHP3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in NCI60_ALL.
